FI70794C - Foerfarande foer stabilisering av en lyofiliserad farmaceutiskinterferonblandning - Google Patents

Foerfarande foer stabilisering av en lyofiliserad farmaceutiskinterferonblandning Download PDF

Info

Publication number: FI70794C
Authority: FI; Finland
Prior art keywords: interferon; amino acid; mixture; glycine; alanine
Prior art date: 1981-12-23

Application number

FI824366A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI70794B (fi

FI824366L (fi

FI824366A0 (fi

Inventor

Henry King Hong Kwan

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-23

Filing date

1982-12-20

Publication date

1986-10-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26989028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI70794(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1982-11-19 Priority claimed from ZA828580A external-priority patent/ZA828580B/xx

1982-12-20 Application filed by Schering Corp filed Critical Schering Corp

1982-12-20 Publication of FI824366A0 publication Critical patent/FI824366A0/fi

1983-06-24 Publication of FI824366L publication Critical patent/FI824366L/fi

1986-07-18 Publication of FI70794B publication Critical patent/FI70794B/fi

1986-10-27 Application granted granted Critical

1986-10-27 Publication of FI70794C publication Critical patent/FI70794C/fi

Links

238000000034 method Methods 0.000 title claims description 19
230000006641 stabilisation Effects 0.000 title description 2
238000011105 stabilization Methods 0.000 title description 2
239000003814 drug Substances 0.000 title 1
102000014150 Interferons Human genes 0.000 claims description 61
108010050904 Interferons Proteins 0.000 claims description 61
229940079322 interferon Drugs 0.000 claims description 61
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 27
239000000203 mixture Substances 0.000 claims description 26
239000000243 solution Substances 0.000 claims description 19
150000001413 amino acids Chemical class 0.000 claims description 17
239000004471 Glycine Substances 0.000 claims description 13
239000007853 buffer solution Substances 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
102000003996 Interferon-beta Human genes 0.000 claims description 6
108090000467 Interferon-beta Proteins 0.000 claims description 6
238000004108 freeze drying Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
102000008100 Human Serum Albumin Human genes 0.000 claims description 5
108091006905 Human Serum Albumin Proteins 0.000 claims description 5
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 5
230000000087 stabilizing effect Effects 0.000 claims description 5
239000008223 sterile water Substances 0.000 claims description 5
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
210000000265 leukocyte Anatomy 0.000 claims description 3
150000001412 amines Chemical class 0.000 claims description 2
150000003862 amino acid derivatives Chemical class 0.000 claims description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 description 14
102000009027 Albumins Human genes 0.000 description 5
108010088751 Albumins Proteins 0.000 description 5
230000000694 effects Effects 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229940047124 interferons Drugs 0.000 description 4
238000003756 stirring Methods 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000003860 storage Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229940000635 beta-alanine Drugs 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
241001337814 Erysiphe glycines Species 0.000 description 1
108010078049 Interferon alpha-2 Proteins 0.000 description 1
102100039350 Interferon alpha-7 Human genes 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
244000005700 microbiome Species 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
-1 pH 7.4 Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)

FI824366A 1981-12-23 1982-12-20 Foerfarande foer stabilisering av en lyofiliserad farmaceutiskinterferonblandning FI70794C (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US33405281A	1981-12-23	1981-12-23
US33405281		1981-12-23
ZA828580A ZA828580B (en)	1981-12-23	1982-11-19	Interferon formulations
ZA8208580		1982-11-19

Publications (4)

Publication Number	Publication Date
FI824366A0 FI824366A0 (fi)	1982-12-20
FI824366L FI824366L (fi)	1983-06-24
FI70794B FI70794B (fi)	1986-07-18
FI70794C true FI70794C (fi)	1986-10-27

Family

ID=26989028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI824366A FI70794C (fi)	1981-12-23	1982-12-20	Foerfarande foer stabilisering av en lyofiliserad farmaceutiskinterferonblandning

Country Status (18)

Country	Link
US (1)	US4496537A (fr)
EP (1)	EP0082481B2 (fr)
AU (1)	AU558966B2 (fr)
CA (1)	CA1207665A (fr)
DE (1)	DE3262575D1 (fr)
DK (1)	DK158873C (fr)
FI (1)	FI70794C (fr)
HK (1)	HK94487A (fr)
HU (1)	HU190649B (fr)
IE (1)	IE54468B1 (fr)
IL (1)	IL67517A (fr)
MY (1)	MY8700705A (fr)
NO (1)	NO161036C (fr)
NZ (1)	NZ202856A (fr)
OA (1)	OA07282A (fr)
PH (1)	PH19869A (fr)
PT (1)	PT76013B (fr)
SG (1)	SG70687G (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4600583A (en) *	1982-09-07	1986-07-15	Tetra Consultants Inc.	Pharmaceutical compositions
US4469228A (en) *	1983-05-31	1984-09-04	Schering Corporation	Interferon kit
JPH0651641B2 (ja) *	1983-08-29	1994-07-06	株式会社ミドリ十字	ガンマ・インターフェロン組成物
JPS6034919A (ja) *	1983-08-04	1985-02-22	Green Cross Corp:The	ガンマ・インタ−フェロン組成物
US4855134A (en) *	1983-10-14	1989-08-08	Sumitomo Pharmaceuticals Company, Limited	Sustained-release preparation
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
EP0168008A3 (fr) *	1984-07-10	1986-12-30	Takeda Chemical Industries, Ltd.	Composition stable d'interféron-gamma
US5196323A (en) *	1985-04-27	1993-03-23	Boehringer Ingelheim International Gmbh	Process for preparing and purifying alpha-interferon
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
DE3628468A1 (de) *	1986-08-21	1988-03-03	Thomae Gmbh Dr K	Neue applikationsformen fuer (alpha)-interferone
CA1320905C (fr) *	1986-11-06	1993-08-03	Joseph M. Cummins	Traitement d'affections immuno-resistantes
US4851220A (en) *	1986-11-26	1989-07-25	Schering Corporation	Stable oleaginous gel
US4853218A (en) *	1987-02-24	1989-08-01	Schering Corporation	Zinc-protamine-alpha interferon complex
US4895716A (en) *	1987-06-09	1990-01-23	Biogen, Inc.	Stabilized formulations of gamma interferons
US4871538A (en) *	1987-07-13	1989-10-03	Schering Corporation	Insoluble copper-alpha interferon complex
US5151265A (en) *	1987-11-03	1992-09-29	Genentech, Inc.	Gamma interferon formulation
US5004605A (en) *	1987-12-10	1991-04-02	Cetus Corporation	Low pH pharmaceutical compositions of recombinant β-interferon
EP0326151B1 (fr) *	1988-01-29	1993-06-16	Sumitomo Pharmaceuticals Company, Limited	Formulations perfectionnées à libération contrôlée
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5165921A (en) *	1989-01-23	1992-11-24	National Geno Sciences, Inc.	Method for treating condyloma acuminatum with interferon
IT1240314B (it) *	1989-09-28	1993-12-07	Immunobiology Research Institutes, Inc.	Formulazioni acquose stabilizzate di piccoli peptidi.
JPH07501320A (ja) *	1991-10-11	1995-02-09	ギリーズ，マーク・セドリック	インタ−フェロン・アルファによる眼線維症の治療
US5863530A (en) *	1991-10-11	1999-01-26	Spruson & Ferguson	Treating ophthalmic fibrosis using interferon-α
AU669132B2 (en) *	1991-10-11	1996-05-30	Mark Cedric Gillies	Treating ophthalmic fibrosis using interferon-alpha
US5236707A (en) *	1991-11-08	1993-08-17	Dallas Biotherapeutics, Inc.	Stabilization of human interferon
LT3987B (en)	1992-02-17	1996-06-25	Fermentas Biotech Inst	Stabilized interferon compositions
US5358708A (en) *	1993-01-29	1994-10-25	Schering Corporation	Stabilization of protein formulations
US6270757B1 (en) *	1994-04-21	2001-08-07	Genetics Institute, Inc.	Formulations for IL-11
US6399296B1 (en) *	1994-07-20	2002-06-04	The General Hospital Corporation	Interaction trap systems for detecting protein interactions
US5766582A (en) *	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
JP2000510813A (ja) *	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
US5656730A (en) *	1995-04-07	1997-08-12	Enzon, Inc.	Stabilized monomeric protein compositions
US6540993B1 (en) *	1995-06-27	2003-04-01	Wyeth	Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) *	1995-06-27	2000-10-03	Genetics Institute	Methods of treating inflammatory bowel diseases by administering IL-11
SI0948358T2 (sl) *	1996-12-24	2012-03-30	Biogen Idec Inc	Stabilne tekoče formulacije interferona
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
DK1017413T4 (da) †	1997-09-23	2008-03-25	Rentschler Biotech Gmbh	Flydende formulering af interferon-beta
PT1039905E (pt) *	1997-10-14	2006-11-30	Eisai Co Ltd	Formulação farmacêutica que compreende glicina como um estabilizador
US7230014B1 (en)	1997-10-14	2007-06-12	Eisai Co., Ltd.	Pharmaceutical formulation comprising glycine as a stabilizer
US8563803B2 (en) *	1997-10-16	2013-10-22	Synageva Biopharma Corp.	Method of making protein in an egg of a transgenic chicken
US20040019923A1 (en) *	1997-10-16	2004-01-29	Ivarie Robert D.	Exogenous proteins expressed in avians and their eggs
US7511120B2 (en) *	1997-10-16	2009-03-31	Synageva Biopharma Corp.	Glycosylated G-CSF obtained from a transgenic chicken
US7129390B2 (en)	1997-10-16	2006-10-31	Avigenics, Inc	Poultry Derived Glycosylated Interferon Alpha 2b
US20090074718A1 (en) *	1997-10-16	2009-03-19	Ivarie Robert D	Avian derived erythropoietin
US20030166525A1 (en) *	1998-07-23	2003-09-04	Hoffmann James Arthur	FSH Formulation
SK287372B6 (sk)	1998-11-12	2010-08-09	Schering Corporation	Spôsob zvýšenia výťažku prostriedku obsahujúceho interferón-alfa
US6281337B1 (en)	1998-11-12	2001-08-28	Schering Corporation	Methods for conversion of protein isoforms
KR100771294B1 (ko) *	1999-12-14	2007-10-29	써모 바이오스타, 인크.	폴리펩티드 및 항원 안정화 희석제
WO2002036627A2 (fr)	2000-11-03	2002-05-10	Pbl Biomedical Laboratories	Interferons, utilisations et compositions associees
US8637077B2 (en)	2000-12-28	2014-01-28	Takeda Pharmaceutical Company Limited	Sustained-release preparation
UY27373A1 (es) *	2001-07-09	2003-02-28	Schering Ag	Formulaciones de interferón beta-humano
DK3025726T3 (da)	2002-01-18	2019-12-09	Biogen Ma Inc	Polyalkylenpolymerforbindelser og anvendelser deraf
US20050232899A1 (en) *	2002-05-31	2005-10-20	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US6830744B2 (en)	2002-05-31	2004-12-14	Aradigm Corporation	Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US7803362B2 (en) *	2003-01-24	2010-09-28	Synageva Biopharma Corp.	Glycosylated interferon alpha
AU2004226666B9 (en) *	2003-04-02	2010-04-08	Ares Trading S.A.	Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
AU2004248931B2 (en) *	2003-06-20	2009-07-16	Ares Trading S.A.	Freeze-dried FSH / LH formulations
DE602005022895D1 (de) *	2004-08-12	2010-09-23	Schering Corp	Stabile pegylierte interferon-formulierung
US20080064862A1 (en) *	2004-12-29	2008-03-13	Avigenics, Inc.	Transgene expression in a avians
US20080299212A1 (en) *	2005-02-25	2008-12-04	Medigenes Co., Ltd	Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum
US8124732B2 (en)	2005-06-24	2012-02-28	Synageva Biopharma Corp.	Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
US20070003564A1 (en) *	2005-06-30	2007-01-04	Hurley John K	Diluent for immunohistochemistry
WO2008048228A2 (fr) *	2005-08-12	2008-04-24	Department Of The Army	Plasma lyophilisé stabilisé par la glycine
CU23432B6 (es)	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US7812127B2 (en)	2006-03-17	2010-10-12	Synageva Biopharma Corp.	Glycosylated human G-CSF
US20090105462A1 (en) *	2006-11-09	2009-04-23	Ivarie Robert D	Glycosylated erythropoietin
PL2097068T3 (pl) *	2006-11-24	2013-12-31	Cadila Healthcare Ltd	Preparaty koniugatów PEG-interferon alfa
US7951368B2 (en)	2007-06-25	2011-05-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
US20100297081A1 (en) *	2007-12-18	2010-11-25	Huang Yanshan	Pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
PT2496246T (pt)	2009-11-03	2018-07-31	Grifols Therapeutics Llc	Composição, método e kit para o inibidor da alfa-1 protease
RU2540480C2 (ru)	2009-11-24	2015-02-10	Грифольс Терапьютикс Инк.	Способы, композиции и наборы для лиофилизации
US20130008191A1 (en) *	2011-07-07	2013-01-10	Suchak Naresh J	Methods for freezing and thawing proteins
ES2824028T3 (es)	2014-08-19	2021-05-11	Biogen Ma Inc	Método de PEGilación
CN106421755A (zh) *	2016-11-03	2017-02-22	广州凯耀资产管理有限公司	一种干扰素组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2553497A (en) *	1946-02-04	1951-05-15	L Inst De Serotherapie Hemopoi	Hemostatic composition of thrombin and glycocoll
US2806815A (en) *	1955-04-12	1957-09-17	Ortho Pharma Corp	Stabilized hyaluronidase
GB866423A (en) *	1958-03-21	1961-04-26	Armour & Co	Improvements in or relating to chymotrypsin solutions
US3016398A (en) *	1959-04-06	1962-01-09	Staley Mfg Co A E	Stabilized phytic acid solutions and methods of preparation thereof
GB900115A (en) *	1960-06-15	1962-07-04	Armour & Co	Improvements in or relating to trypsin solutions
JPS5495795A (en) *	1978-01-13	1979-07-28	Toray Ind Inc	Production of interferon
IN150740B (fr) *	1978-11-24	1982-12-04	Hoffmann La Roche
JPS55102519A (en) *	1979-01-31	1980-08-05	Green Cross Corp:The	Stabilization of interferon
US4198479A (en) *	1979-03-30	1980-04-15	Merck & Co., Inc.	Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4252791A (en) *	1979-10-19	1981-02-24	The Medical College Of Wisconsin, Inc.	Interferon stabilization
US4337242A (en) *	1980-02-05	1982-06-29	Merck & Co., Inc.	Vaccine stabilizer containing L-glutamic acid and L-arginine
FR2505657A1 (fr) *	1981-05-13	1982-11-19	Pasteur Institut	Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation

1982
- 1982-12-15 DE DE8282111665T patent/DE3262575D1/de not_active Expired
- 1982-12-15 EP EP82111665A patent/EP0082481B2/fr not_active Expired - Lifetime
- 1982-12-20 AU AU91688/82A patent/AU558966B2/en not_active Expired
- 1982-12-20 FI FI824366A patent/FI70794C/fi not_active IP Right Cessation
- 1982-12-20 IL IL67517A patent/IL67517A/xx not_active IP Right Cessation
- 1982-12-20 NZ NZ202856A patent/NZ202856A/en unknown
- 1982-12-20 NO NO82824285A patent/NO161036C/no not_active IP Right Cessation
- 1982-12-20 PH PH28296A patent/PH19869A/en unknown
- 1982-12-21 PT PT76013A patent/PT76013B/pt unknown
- 1982-12-21 OA OA57876A patent/OA07282A/fr unknown
- 1982-12-21 CA CA000418237A patent/CA1207665A/fr not_active Expired
- 1982-12-21 DK DK565882A patent/DK158873C/da not_active IP Right Cessation
- 1982-12-21 IE IE3046/82A patent/IE54468B1/en not_active IP Right Cessation
- 1982-12-22 HU HU824137A patent/HU190649B/hu unknown
1983
- 1983-09-16 US US06/532,886 patent/US4496537A/en not_active Expired - Lifetime
1987
- 1987-08-27 SG SG706/87A patent/SG70687G/en unknown
- 1987-12-10 HK HK944/87A patent/HK94487A/en not_active IP Right Cessation
- 1987-12-30 MY MY705/87A patent/MY8700705A/xx unknown

Also Published As

Publication number	Publication date
OA07282A (fr)	1984-11-30
PT76013A (en)	1983-01-01
FI70794B (fi)	1986-07-18
DK158873C (da)	1990-12-31
DK565882A (da)	1983-06-24
NO161036B (no)	1989-03-20
FI824366L (fi)	1983-06-24
FI824366A0 (fi)	1982-12-20
CA1207665A (fr)	1986-07-15
NO161036C (no)	1989-06-28
IE823046L (en)	1983-06-23
DK158771B (da)	1990-07-16
EP0082481A1 (fr)	1983-06-29
PH19869A (en)	1986-08-13
MY8700705A (en)	1987-12-31
IL67517A0 (en)	1983-05-15
NZ202856A (en)	1985-12-13
IE54468B1 (en)	1989-10-25
SG70687G (en)	1988-02-19
DE3262575D1 (en)	1985-04-18
AU9168882A (en)	1983-06-30
HU190649B (en)	1986-09-29
AU558966B2 (en)	1987-02-19
EP0082481B2 (fr)	1990-09-12
HK94487A (en)	1987-12-18
US4496537A (en)	1985-01-29
PT76013B (en)	1986-03-11
EP0082481B1 (fr)	1985-03-13
IL67517A (en)	1988-11-30
DK158873B (da)	1990-07-30
NO824285L (no)	1983-06-24

Legal Events

Date	Code	Title	Description
2004-08-31	MA	Patent expired	Owner name: SCHERING CORPORATION

Publication	Publication Date	Title
FI70794B (fi)	1986-07-18	Foerfarande foer stabilisering av en lyofiliserad farmaceutiskinterferonblandning
EP0444692B1 (fr)	1995-01-11	Composition contenant de la thrombine administrable par voie orale
CA1330301C (fr)	1994-06-21	Preparations de proteines humaines stabilisees
US5744132A (en)	1998-04-28	Formulations for IL-12
US5766582A (en)	1998-06-16	Stable, aqueous alfa interferon solution formulations
US4895716A (en)	1990-01-23	Stabilized formulations of gamma interferons
SK138395A3 (en)	1997-02-05	Oxygen-reduced aqueous solution of factor viii
EP0590514B1 (fr)	1996-06-26	Composition et procédé pour conserver du sang
RU2095081C1 (ru)	1997-11-10	Фармацевтическая композиция антивирусного действия
EP1058547B1 (fr)	2005-11-23	Compositions pharmaceutiques contenant un 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate sodique, inhibiteur des phospholipases
CA1313131C (fr)	1993-01-26	Formules d'application de l'interferon-
EP0399781B1 (fr)	1992-12-23	Préparation de calcitonine stabilisée
KR880002037B1 (ko)	1988-10-13	인터페론 조성물 및 이의 제조방법
KR100560697B1 (ko)	2006-03-16	알부민을 함유하지 않는 에리스로포이에틴 제제
WO1992009277A1 (fr)	1992-06-11	Source nutritive
EP0397147B1 (fr)	1995-01-18	Solutions stables de dérivés de la rebeccamycine et leur préparation
HU205555B (en)	1992-05-28	Process for producing stabilized leukocyte interferons
JPS60260523A (ja)	1985-12-23	インタ−フエロンの凍結乾燥医薬組成物
JP3088744B2 (ja)	2000-09-18	フィブロネクチン組成物
KR930004600B1 (ko)	1993-06-01	γ-인터페론 조성물의 제조방법
WO2002060475A1 (fr)	2002-08-08	Procedes pour stabiliser des proteines sanguines lyophilisees
KR19990085129A (ko)	1999-12-06	안정한 α-인터페론 용액 제제
JPS62149623A (ja)	1987-07-03	安定なｇｒｆ製剤
MXPA97002578A (en)	1997-12-01	Alfa-interferonestable acu solution formulations
MXPA00008596A (en)	2002-03-05	Pharmaceutical compositions containing the phospholipase inhibitor sodium [[3-(2-amino-1, 2-dioxoethyl)- 2-ethyl-1-phenylmethyl) -1h-indol-4-yl]oxy]acetate